Two way street: Industry/patient dialogue and its role in market access

How can we make the pharma world more patient centric?

Market access focus: What is the purpose of market access?

Could market access be comparable to the Force in Star Wars, or any Disney, sci-fi, or Harry Potter film?

Market access focus: GM devolution: what has it achieved so far?

Have Greater Manchester achieved anything in three years?
hands holding matching drug containers to show adalimumab biosimilars

Market access focus: The Biosimilars Battle

Read this article in our Pf Magazine Market Access Special Edition here.  In 2017, Adelphi published research around biosimilars to assess the overall impact on patients,...

Market access focus: Working with the broader health economy

Read this article in our Pf Magazine Market Access Special Edition here.  Pharma really has to start to engage beyond traditional organisations; some companies are...

Market Access focus: The changing landscape of patient access to new medicines

Read this article in our Pf Magazine Market Access Special Edition here.  In a constantly changing market access landscape, industry has a greater range of...

Market Access focus: What does modern market access really mean?

Read this article in our Pf Magazine Market Access Special Edition here.  There is no one definition for modern market access – what does it...

Market Access focus: Where are we now?

Read this article in our Pf Magazine Market Access Special Edition here.  The PM Society Market Access interest group (MAIG) recently conducted a needs analysis...

“Life-changing” developments in the treatment of severe asthma

Asthma is one of the most prevalent long term conditions in the UK, affecting 5.4 million people, of whom nearly three million take treatment....

Duchenne UK works hard to find a cure for DMD

Duchenne UK’s co-founder and joint CEO Emily Crossley shares her vision for finding a cure for Duchenne Muscular Dystrophy (DMD) patients. DMD is a devastating...

Latest articles

Maxwellia makes two new appointments

Maxwellia expand their team with two new appointments

Maxwellia has expanded their team of switch experts with two new appointments following their relocation to the Alderley Park Accelerator. 
BMS & Boston Medical Center enter collaboration

BMS & Boston Medical Center announce research collaboration

BMS & Boston Medical Center enter research collaboration to investigate markers of immuno-oncology response and resistance Bristol-Myers Squibb Company...
Syringe with liquid

EC approves KEYTRUDA® as adjuvant therapy

MSD (Merck in the U.S. and Canada) has announced that the European Commission has approved its anti-PD-1 therapy, KEYTRUDA (pembrolizumab), for the adjuvant treatment...